Alzheon

Framingham, United States

Alzheon is a clinical-stage biotechnology company that develops treatment for neurodegenerative disorders.

Jun 2024

Series E

Top Investors

Ally Bridge GroupNational Institute on AgingScott H. CohenAlerce Medical Technology Partners

19,000+ verified contacts

Emails, phones & LinkedIn profiles

Who are Alzheon's investors?

Alzheon's investors include Ally Bridge Group, National Institute on Aging, Scott H. Cohen, Alerce Medical Technology Partners.

Where is Alzheon headquartered?

Alzheon is headquartered in Framingham, United States.

What does Alzheon do?

Alzheon is a clinical-stage biotechnology company that develops treatment for neurodegenerative disorders.

What stage is Alzheon at?

Alzheon is at the Series E stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated June 12, 2024.

MLA

"Alzheon — Funding & Investors." VCBacked, June 12, 2024, https://www.vcbacked.co/company/alzheon. Accessed July 1, 2026.

APA

VCBacked. (2024). Alzheon — Funding & Investors. Retrieved July 1, 2026, from https://www.vcbacked.co/company/alzheon

Wikipedia (cite web)

{{cite web |title=Alzheon — Funding & Investors |url=https://www.vcbacked.co/company/alzheon |website=VCBacked |access-date=July 1, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated June 12, 2024.